Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

Lisa Baumann Kreuziger; Michael Streiff

doi:10.1182/asheducation-2016.1.206

Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

Lisa Baumann Kreuziger, Michael Streiff

School of Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?

Original language	English (US)
Pages (from-to)	206-207
Number of pages	2
Journal	Hematology
Volume	2016
Issue number	1
DOIs	https://doi.org/10.1182/asheducation-2016.1.206
State	Published - 2016

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/asheducation-2016.1.206

Cite this

@article{031deaf82e724c078cca2dd175186a75,

title = "Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer",

abstract = "A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?",

author = "Kreuziger, {Lisa Baumann} and Michael Streiff",

note = "Funding Information: Conflict-of-interest disclosure: L.B.K. declares no competing financial interests. M.S. has received research funding from Janssen, Portola, Roche, and PCORI and has consulted for Bio2Medical, Janssen, CSL Behring, and Merck.",

year = "2016",

doi = "10.1182/asheducation-2016.1.206",

language = "English (US)",

volume = "2016",

pages = "206--207",

journal = "Hematology",

issn = "1520-4391",

publisher = "American Society of Hematology",

number = "1",

}

TY - JOUR

T1 - Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

AU - Kreuziger, Lisa Baumann

AU - Streiff, Michael

N1 - Funding Information: Conflict-of-interest disclosure: L.B.K. declares no competing financial interests. M.S. has received research funding from Janssen, Portola, Roche, and PCORI and has consulted for Bio2Medical, Janssen, CSL Behring, and Merck.

PY - 2016

Y1 - 2016

N2 - A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?

AB - A 68-year-old man developed a right femoral vein deep vein thrombosis and bilateral pulmonary embolism while receiving chemotherapy for stage IV prostate cancer. His creatinine at diagnosis is 1.4 mg/dL with an estimated clearance of 63 mL/min. In patients with cancer, should low-molecular-weight heparin treatment be dosed according to weight, or adjusted using anti-Xa levels?

UR - http://www.scopus.com/inward/record.url?scp=85020374411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020374411&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.206

DO - 10.1182/asheducation-2016.1.206

M3 - Article

C2 - 27913481

AN - SCOPUS:85020374411

SN - 1520-4391

VL - 2016

SP - 206

EP - 207

JO - Hematology

JF - Hematology

IS - 1

ER -

Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this